Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Indiana University Health

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 14
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 14
Rounds per year 0.56
Lead investments 0
Exits 1
Key employees Soon

Areas of investment

  • Non Profit
  • Health Care
  • Education
  • Service Industry
  • Pharmaceutical
Summary

The main office of represented Corporate Investor is situated in the Indianapolis. The venture was found in North America in United States.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Indiana University Health, startups are often financed by Sanderling Ventures, River Cities Capital Funds, Triathlon Medical Venture Partners. The meaningful sponsors for the fund in investment in the same round are Triathlon Medical Venture Partners, Sanderling Ventures, River Cities Capital Funds. In the next rounds fund is usually obtained by Silicon Valley Bank, MidCap Financial.

The fund has no exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 16-20 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight PerfectServe, Endocyte. Among the most popular fund investment industries, there are Health Care, Mobile.

The fund is generally included in less than 2 deals every year. The high activity for fund was in 2015. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2011.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Carlyle Global Partners District of Columbia, United States, Washington
Chilton Investment Connecticut, Stamford, United States
Claytonia Capital California, San Francisco, United States
Ghilotti Brothers California, San Rafael, United States
Paladin Capital Group District of Columbia, United States, Washington
Retinal Degeneration Fund North Carolina, Raleigh, United States
Ringier Switzerland, Zürich, Zurich
Starta Accelerator New York, New York, United States
Yatra Angel Network India, Maharashtra, Mumbai
Zhonglu Investment Management China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Endocyte

Biotechnology
Health Care
Pharmaceutical
$26M19 Jan 2010 Indiana, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Indiana University Health?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 14
Average round size 3M
Rounds per year 0.56
Peak activity year 2021
Lead investments 0
Exits 1
Group Appearance index 0.14

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Endocyte

Biotechnology
Health Care
Pharmaceutical
$26M19 Jan 2010 Indiana, United States
Crunchbase icon

Content report

The following text will be sent to our editors: